TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30321900
Drug: Classical Massage
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical Massage Therapy (KMT)
Study: 30321900
Drug: Acupuncture Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture Therapy (AKU)
Study: 12215984
Drug: Ropivacaine 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 5.0 mg/mL
Study: 23222363
Drug: Ropivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 7.5 mg/mL
Study: 10412335
Drug: Environmental controls
Normalized name: ZINC OXIDE 225 mg in 100 mL TOPICAL CREAM [ENVIRONMENTAL DEFENSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Environmental controls (wrapping mattress with vinyl cover, washing bedding with hot water every two weeks, removal of soft furniture, wet cleaning bedroom floor daily)
Study: 6464626
Drug: Postoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative treatment without nasogastric tubes
Study: 19024521
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg twice daily for 7 days
Study: 9272808
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with a history of injection drug use (IDU)
Study: 9272808
Drug: Patients acknowledging
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients acknowledging continued drug use
Study: 9272808
Drug: Patients denying
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients denying any recent drug use
Study: 7878558
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg terbutaline from a pressurised metered dose inhaler (MDI) with spacer (4 x 0.25 mg doses)
Study: 2975458
Drug: Incremental doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental doses of synthetic atrial natriuretic peptide in sodium-replete dogs
Study: 2975458
Drug: Incremental doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental doses of synthetic atrial natriuretic peptide in sodium-depleted dogs
Study: 24535888
Drug: Fexinidazole single
Normalized name: fexinidazole
DrugBank: Fexinidazole (DB12265)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexinidazole single dose (100 to 3,600 mg)
Study: 21823199
Drug: Group Cognitive-Behavioural
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive-Behavioural Therapy (CBT)
Study: 17573387
Drug: 900 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg/day UDCA
Study: 2547680
Drug: Enalapril, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 0.5 mg.kg‐1.day‐1 for 4 weeks
Study: 1095108
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of Solcoseryl
Study: 29522089
Drug: Artemisinin-based combination
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin-based combination therapy
Study: 10023943
Drug: Bisoprolol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 1.25 mg daily, increased to a maximum of 10 mg per day
Study: 2110430
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and hydroxychloroquine (n = 11)
Study: 21869712
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (TA) 40 mg
Study: 27856801
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate (MA) 40 mg
Study: 25890808
Drug: Mobile-bearing TKA
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile-bearing TKA implant
Study: 25890808
Drug: Fixed-bearing TKA
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed-bearing TKA implant
Study: 23376864
Drug: Sildenafil, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil, 50 to 100 mg as needed
Study: 21795740
Drug: Partially hydrogenated
Normalized name: SOY OIL,PARTIALLY HYDROGENATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially hydrogenated soybean oil (15.7 g/day IP‐TFA)
Study: 18003511
Drug: 2 ng/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ng/ml effect compartment controlled remifentanil
Study: 11465304
Drug: Tapered discontinuation
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapered discontinuation of cyclosporin microemulsion
Study: 11465304
Drug: Abrupt discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrupt discontinuation of cyclosporin microemulsion
Study: 4063085
Drug: Indoor therapy
Normalized name: Cleartime Indoor & Outdoor Allergies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoor therapy exercises with elements of games (B2 subgroup)
Study: 4063085
Drug: Indoor therapy
Normalized name: Cleartime Indoor & Outdoor Allergies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoor therapy exercises with 5.2 mg of nitrong 1 hour prior to PT (B3 subgroup)
Study: 29558650
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group therapy (CBGT)
Study: 29195836
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to monotherapy from two non‐clozapine oral antipsychotics
Study: 29195836
Drug: Stay on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stay on polypharmacy with two non‐clozapine oral antipsychotics
Study: 29195836
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to monotherapy from combinations involving clozapine or an injectable antipsychotic
Study: 17627166
Drug: Cefazolin 1
Normalized name: cefazolin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 1 g (first-generation cephalosporin)
Study: 17627166
Drug: Cefuroxime 750
Normalized name: cefuroxime 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 750 mg (second-generation cephalosporin)
Study: 21443601
Drug: Alitretinoin 30
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alitretinoin 30 mg and simvastatin 40 mg
Study: 21443601
Drug: Alitretinoin 30
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alitretinoin 30 mg and ciclosporin A 300 mg
Study: 21443601
Drug: Alitretinoin 30
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alitretinoin 30 mg
Study: 19347367
Drug: Zinc supplements
Normalized name: Zinc Supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplements (10 mg/day) in frequent relapsers
Study: 3355578
Drug: 170 mg
Normalized name: mannitol 170 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 170 mg alpha‐tocopherol
Study: 16948779
Drug: Dietary supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplementation containing melatonin, l‐tryptophan, vitamin B6, folic acid, vitamin B12, methionine and betaine for 40 days.
Study: 16948779
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole for 40 days.
Study: 24172641
Drug: Cryoultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryoultrasound therapy
Study: 25470572
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride extended-release (MPH-MLR)
Study: 16804432
Drug: MMRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV vaccine (one of 3 consistency lots)
Study: 16804432
Drug: MMR +
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR + V (administered at separate injection sites)
Study: 12450703
Drug: MMRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV vaccine
Study: 14530872
Drug: 30 microk/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 microk/kg PEG‐rHuMGDF administered on day ‐6 followed by 10 microg/kg on days ‐5 to day 6 (n=35)
Study: 14530872
Drug: Placebo as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as a single dose on day ‐6 (n=9)
Study: 14530872
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered on day ‐6 to day 6 (n=9)
Study: 11030677
Drug: Routine speech
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine speech and language therapy
Study: 1984187
Drug: Low-protein, low-phosphorus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein, low-phosphorus diet (0.6 g of protein per kg of ideal body weight per day, 500 to 1000 mg of phosphorus, 2000 mg of sodium)
Study: 1984187
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (at least 1 g of protein per kg per day, 1000 mg of phosphorus, 2000 mg of sodium)
Study: 29214015
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative treatment (SMT)
Study: 29792372
Drug: THC:CBD oromucosal
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC:CBD oromucosal spray (Sativex®)
Study: 17760536
Drug: Quadrant-wise basic
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrant-wise basic periodontal therapy (BPT)
Study: 8151910
Drug: SBT/CPZ monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBT/CPZ monotherapy
Study: 8151910
Drug: SBT/CPZ combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBT/CPZ combined therapy
Study: 1908584
Drug: No pill
Normalized name: Beano Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pill
Study: 26605240
Drug: Memantine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine plus atypical antipsychotic
Study: 18459553
Drug: Polyethylene glycol-electrolyte
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol-electrolyte lavage solution (PEG-ELS)
Study: 16298243
Drug: Galantamine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (4 mg bid) for 7 days
Study: 14624153
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b daily (3 million units) plus ribavirin
Study: 14624153
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b thrice-weekly (3 million units) plus ribavirin
Study: 10963197
Drug: sirolimus 2
Normalized name: sirolimus 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sirolimus 2 mg daily (n=284)
Study: 10963197
Drug: sirolimus 5
Normalized name: SIROLIMUS 5 mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION [FYARRO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: sirolimus 5 mg daily (n=274)
Study: 1565457
Drug: Postoperative subconjunctival
Normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative subconjunctival injections of 5-fluorouracil (5-FU)
Study: 31812339
Drug: 268 mg
Normalized name: vitamin E 268 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 268 mg α‐T
Study: 31812339
Drug: 526 mg
Normalized name: PhysioSol 30 MG / 37 MG / 222 MG / 526 MG / 502 MG per 100 ML Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 526 mg TRF
Study: 29333776
Drug: L+SRP (Nd:
Approvals — FDA: no, EMA: no, PMDA: no
Description: L+SRP (Nd: YAG laser followed by Scaling and Root Planning)
Study: 24647388
Drug: Whole blood
Normalized name: Whole blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole blood (EDTA and heparin) stored with an icepack for 24 or 48 hours
Study: 12710865
Drug: Memantine 10
Normalized name: Memantine 10mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 10 mg/day
Study: 3902676
Drug: Fenquizone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenquizone (10 mg)
Study: 1778085
Drug: Chlorthalidone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (25 mg)
Study: 30027269
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (200,000 IU initial bolus followed by 100,000 IU monthly)
Study: 26715500
Drug: Intravenous cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefuroxime 1.5 g (group A)
Study: 16038473
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine (ddI) for 4 weeks in addition to current combination therapy
Study: 12372925
Drug: Ionic X-ray
Normalized name: lactose, x-ray exposed (1000 rad)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ionic X-ray contrast agent (ioxaglate)
Study: 12372925
Drug: Non-ionic X-ray
Normalized name: lactose, x-ray exposed (1000 rad)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ionic X-ray contrast agent (iopromide)
Study: 1951234
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg bid famotidine
Study: 7038565
Drug: Metered aerosol
Normalized name: nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered aerosol dose of fenoterol
Study: 7038565
Drug: Aerosol inhalation
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol inhalation
Study: 7038565
Drug: Powder inhalation
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder inhalation
Study: 26492879
Drug: Basic Body
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic Body Awareness Therapy
Study: 24163324
Drug: Carbon nanoparticle
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon nanoparticle suspension injection
Study: 21196444
Drug: Intracoronary adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary adenosine 4 mg
Study: 19644189
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of valacyclovir daily for 6 months
Study: 19644189
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of valacyclovir daily for 12 months
Study: 19644189
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of valacyclovir daily for 24 months
Study: 19644189
Drug: Topical antiseptics
Normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antiseptics (control group)
Study: 2015724
Drug: 1 gm
Normalized name: Ifex 1 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gm acetaminophen
Study: 7235205
Drug: Microcrystalline theophylline
Normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline theophylline tablet (Nuelin)
Study: 28426104
Drug: Amrubicin (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrubicin (35 mg/m2 on days 1-3 every 3 weeks)
Study: 28341108
Drug: Docetaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60 mg/m2 on day 1 every 3 weeks)
Study: 19108379
Drug: Lugua polypeptide
Normalized name: Heme iron polypeptide
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lugua polypeptide injection (16 mg per day for 2 weeks)
Study: 19108379
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg twice a day for 2 weeks)
Study: 15608809
Drug: Green Prescription
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green Prescription physical activity counselling programme (verbal advice and written exercise prescription with telephone follow-up)
Study: 10517718
Drug: Unconventional therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unconventional therapies
Study: 6169671
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of human leukocyte interferon (HLI) ointment (4,000 units/g) for 4 weeks
Study: 6169671
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of human leukocyte interferon (HLI) in the form of powder and solution
Study: 6169671
Drug: Combined local
Normalized name: Local hemostatic combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined local and general therapy
Study: 31841496
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of RFA with verapamil and 5-FU
Study: 31841496
Drug: RFA as
Normalized name: Rfaudraksha resin
DrugBank: Acacia (DB10451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RFA as monotherapy or in combination with chemotherapy
Study: 24602923
Drug: Simeprevir (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir (150 mg, once daily) and peg-interferon α-2a and ribavirin (PR)
Study: 15914936
Drug: ICD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD treatment
Study: 16267706
Drug: Postoperative radio-chemotherapy
Normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative radio-chemotherapy
Study: 16267706
Drug: No postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postoperative therapy
Study: 10395859
Drug: 3.5% gel
Normalized name: NONOXYNOL-9 3.5% GEL,VAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5% gel (Advantage-24)
Study: 7759462
Drug: Midaglizole (MID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midaglizole (MID) 200 mg pre- and post-treatment
Study: 7759462
Drug: Midaglizole (MID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midaglizole (MID) 200 mg pretreatment
Study: 7759462
Drug: Midaglizole (MID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midaglizole (MID) 200 mg posttreatment
Study: 31975265
Drug: Compliant antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compliant antibiotics dosing
Study: 14996523
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide via pressurized metered-dose inhaler
Study: 30447891
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate 524 mg administered 30 min before DMF
Study: 27753427
Drug: Video chat
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Video chat monitoring for pill-taking adherence
Study: 26516614
Drug: l-dopa (Levodopa)
Normalized name: α-methyl-L-dopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: l-dopa (Levodopa) administered preoperatively
Study: 2050169
Drug: Both antidepressants
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both antidepressants (amitriptyline and imipramine)
Study: 6364591
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) ointment (200 mg applied three times a day for 3 weeks)
Study: 14994322
Drug: Quetiapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (mean daily dose 439.5 mg, range 150-750 mg)
Study: 14994322
Drug: Quetiapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (mean daily dose 438.5 mg, range 150-750 mg)
Study: 22348468
Drug: DHA-enriched fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-enriched fish oil supplement
Study: 30195244
Drug: Grilled fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grilled fish (100 g per day)
Study: 28712537
Drug: Bilateral, subretinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral, subretinal injection of 1·5×10^11 vector genomes of voretigene neparvovec in 0·3 mL total volume
Study: 28712537
Drug: Bilateral, subretinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral, subretinal injection of voretigene neparvovec
Study: 24821885
Drug: Subcutaneous rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous rituximab (1,400 mg)
Study: 19182179
Drug: Risperidone 1.5-6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 1.5-6.0 mg/day (regimen A)
Study: 19182179
Drug: Risperidone 0.15-0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 0.15-0.6 mg/day (regimen B)
Study: 8541533
Drug: 1,000 U
Normalized name: vitamin E 1,000 unit ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 U rHuEpo daily subcutaneously for 8 weeks
Study: 8541533
Drug: 2,000 U
Normalized name: AHF 2,000 UNIT/VWF 800 UNIT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,000 U rHuEpo daily subcutaneously for 8 weeks
Study: 8541533
Drug: 5,000 U
Normalized name: Decara 25,000 UNT Vegicaps
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 U rHuEpo daily subcutaneously for 8 weeks
Study: 8541533
Drug: 10,000 U
Normalized name: Erwinaze 10,000 UNT Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10,000 U rHuEpo daily subcutaneously for 8 weeks
Study: 2136809
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg toremifene
Study: 16890670
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg toremifene
Study: 16890670
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg toremifene
Study: 31770513
Drug: CsA CE
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA CE low-dose (0.1% eye drops, twice daily + vehicle twice daily)